Inventor

KANG CHANG-YUIL

KR11 patents

⚠️ This page may combine multiple inventors who share the name “KANG CHANG-YUIL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LG CHEMICAL LTD

2 patents

US5928893AJul 27, 1999

Monoclonal antibody specific for human 4-1BB and cell line producing same

LG CHEMICAL LTD164 citations95

US6458934B1Oct 1, 2002

Humanized antibody specific for human 4-1BB

LG CHEMICAL LTD73 citations91

KANG CHANG-YUIL

2 patents

US9518126B2Dec 13, 2016

Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

KANG CHANG-YUIL10 citations80

US8883746B2Nov 11, 2014

α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient

KANG CHANG-YUIL3 citations53

KANG CHANG YUIL

1 patent

US8617546B2Dec 31, 2013

Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody

KANG CHANG YUIL163 citations97

LG CHEM INVESTMENT LTD

1 patent

US6747050B1Jun 8, 2004

Isoxazoline derivative and a process for the preparation thereof

LG CHEM INVESTMENT LTD23 citations89

LEE JOON YOUB

1 patent

US8445268B2May 21, 2013

Her-2/neu DNA vaccine having anti-cancer activity

LEE JOON YOUB10 citations79

KOREA FOOD RES INST

1 patent

US10016475B2Jul 10, 2018

Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients

KOREA FOOD RES INST4 citations62

SEOUL NAT UNIV IND FOUNDATION

1 patent

US8003093B2Aug 23, 2011

B cell-based vaccine loaded with the ligand of natural killer T cell and antigen

SEOUL NAT UNIV IND FOUNDATION0 citations47

CELLID CO LTD

1 patent

US12098384B2Sep 24, 2024

Adenoviral vector not including replication competent adenovirus, and use thereof

CELLID CO LTD0 citations42

SEOUL NAT UNIV R&DB FOUNDATION

1 patent

US10443040B2Oct 15, 2019

Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereof

SEOUL NAT UNIV R&DB FOUNDATION0 citations30